BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 26065249)

  • 1. [Expressing foreign genes by Newcastle disease virus for cancer therapy].
    Bai FL; Tian H; Yu QZ; Renl GP; Li DS
    Mol Biol (Mosk); 2015; 49(2):195-204. PubMed ID: 26065249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy.
    Cheng X; Wang W; Xu Q; Harper J; Carroll D; Galinski MS; Suzich J; Jin H
    J Virol; 2016 Jun; 90(11):5343-5352. PubMed ID: 27009956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncolytic therapy and gene therapy for cancer: recent advances in antitumor effects of Newcastle disease virus.
    Huang Z; Liu M; Huang Y
    Discov Med; 2020; 30(159):39-48. PubMed ID: 33357361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Newcastle disease virus as an oncolytic agent.
    Ravindra PV; Tiwari AK; Sharma B; Chauhan RS
    Indian J Med Res; 2009 Nov; 130(5):507-13. PubMed ID: 20090097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and clinical usage of newcastle disease virus in cancer therapy.
    Lam HY; Yeap SK; Pirozyan MR; Omar AR; Yusoff K; Suraini AA; Abd-Aziz S; Alitheen NB
    J Biomed Biotechnol; 2011; 2011():718710. PubMed ID: 22131816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Progress in using Newcastle disease virus for tumor therapy: a review].
    Wu Y; Hao J; Li D
    Sheng Wu Gong Cheng Xue Bao; 2010 Aug; 26(8):1031-6. PubMed ID: 21090105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma.
    Buijs P; van Nieuwkoop S; Vaes V; Fouchier R; van Eijck C; van den Hoogen B
    Viruses; 2015 Jun; 7(6):2980-98. PubMed ID: 26110582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Newcastle disease virus: a promising agent for tumour immunotherapy.
    Zhao L; Liu H
    Clin Exp Pharmacol Physiol; 2012 Aug; 39(8):725-30. PubMed ID: 22211810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy.
    Elankumaran S; Chavan V; Qiao D; Shobana R; Moorkanat G; Biswas M; Samal SK
    J Virol; 2010 Apr; 84(8):3835-44. PubMed ID: 20147405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells.
    Jiang K; Song C; Kong L; Hu L; Lin G; Ye T; Yao G; Wang Y; Chen H; Cheng W; Barr MP; Liu Q; Zhang G; Ding C; Meng S
    BMC Cancer; 2018 Jul; 18(1):746. PubMed ID: 30021550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance.
    Schirrmacher V
    Expert Opin Biol Ther; 2015; 15(12):1757-71. PubMed ID: 26436571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic Newcastle disease virus expressing chimeric antibody enhanced anti-tumor efficacy in orthotopic hepatoma-bearing mice.
    Wei D; Li Q; Wang XL; Wang Y; Xu J; Feng F; Nan G; Wang B; Li C; Guo T; Chen ZN; Bian H
    J Exp Clin Cancer Res; 2015 Dec; 34():153. PubMed ID: 26689432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction of recombinant Newcastle disease virus Italien strain for oncolytic virotherapy of tumors.
    Wei D; Sun N; Nan G; Wang Y; Liu HQ; Peeters B; Chen ZN; Bian H
    Hum Gene Ther; 2012 Jul; 23(7):700-10. PubMed ID: 22372930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic therapy of a recombinant Newcastle disease virus D90 strain for lung cancer.
    Chai Z; Zhang P; Fu F; Zhang X; Liu Y; Hu L; Li X
    Virol J; 2014 May; 11():84. PubMed ID: 24885546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
    Vijayakumar G; McCroskery S; Palese P
    J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intratumoral Virotherapy with Wild-Type Newcastle Disease Virus in Carcinoma Krebs-2 Cancer Model.
    Yurchenko KS; Glushchenko AV; Gulyaeva MA; Bi Y; Chen J; Shi W; Adamenko LS; Shestopalov AM
    Viruses; 2021 Mar; 13(4):. PubMed ID: 33806229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy.
    Bai FL; Yu YH; Tian H; Ren GP; Wang H; Zhou B; Han XH; Yu QZ; Li DS
    Cancer Biol Ther; 2014 Sep; 15(9):1226-38. PubMed ID: 24971746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mesenchymal stem cells enhance the oncolytic effect of Newcastle disease virus in glioma cells and glioma stem cells via the secretion of TRAIL.
    Kazimirsky G; Jiang W; Slavin S; Ziv-Av A; Brodie C
    Stem Cell Res Ther; 2016 Oct; 7(1):149. PubMed ID: 27724977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Newcastle disease virus mediated dendritic cell activation and cross-priming tumor-specific immune responses ex vivo.
    Xu Q; Rangaswamy US; Wang W; Robbins SH; Harper J; Jin H; Cheng X
    Int J Cancer; 2020 Jan; 146(2):531-541. PubMed ID: 31584185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of the proapoptotic properties of newcastle disease virus promotes tumor remission in syngeneic murine cancer models.
    Cuadrado-Castano S; Ayllon J; Mansour M; de la Iglesia-Vicente J; Jordan S; Tripathi S; García-Sastre A; Villar E
    Mol Cancer Ther; 2015 May; 14(5):1247-58. PubMed ID: 25761895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.